Avaí Bio and Austrianova Announce Publication in Frontiers in Aging Journal Highlighting Novel Cell Encapsulation-Based Approach to Sustained Klotho Delivery

Avaí Bio and Austrianova report in vitro Klotho production milestone via peer-reviewed publication.

What the company is saying

Avaí Bio, Inc. (OTCQB:AVAI) and its joint venture partner Austrianova are highlighting the publication of a peer-reviewed article in Frontiers in Aging, which reviews the Klotho protein's role in aging and details their technical approach to sustained Klotho delivery. The company emphasizes that Klothonova, their 50/50 joint venture, has achieved long-term Klotho production and secretion in vitro using Austrianova’s Cell-in-a-Box® encapsulation technology. The announcement frames this in vitro result as a significant milestone and positions the encapsulation platform as a potential solution to the challenge of maintaining therapeutic Klotho levels. The tone is optimistic, with both Prof. Walter H. Gunzburg (Chairman and CSO of Austrianova) and CEO Brian Salmons stressing the scientific rigor of the publication and the platform’s future potential. The company also underscores the broader applicability of the encapsulation technology for other cell-based therapies. However, the communication is careful to state that further studies are needed for dosing, safety, and efficacy before clinical translation.

What the data suggests

The only realised milestone is the successful generation of Cell-in-a-Box®-encapsulated cells that produce and secrete Klotho protein in vitro. This is an early-stage, laboratory-based achievement, not yet validated in animal models or humans. The joint venture structure is clearly defined as 50/50 between Avaí Bio and Austrianova. Austrianova is described as having over 50 peer-reviewed publications, but no financial, operational, or clinical outcome data are disclosed. All claims regarding therapeutic impact, clinical efficacy, or broader platform applications remain forward-looking. The data quality is high for scientific process transparency but incomplete for financial or commercial assessment. The evidence supports technical progress at the preclinical research stage, with all translational and commercial milestones still ahead.

Analysis

The announcement is upbeat, highlighting the publication of a peer-reviewed article and the technical milestone of achieving in vitro Klotho production using encapsulated cells. However, most of the claims regarding therapeutic impact, clinical efficacy, and the broader potential of the technology are forward-looking and aspirational, with no in vivo, preclinical, or clinical data disclosed. The only realised milestone is successful in vitro production and secretion of Klotho, which, while important, is an early-stage achievement. The language inflates the signal by emphasizing the platform's transformative potential and the program's trajectory toward sustainable, long-term Klotho delivery, despite the need for substantial further studies. The capital intensity flag is triggered by references to developing innovative cell-based therapies and long-term production platforms, which typically require significant investment and have long, uncertain timelines to commercialisation. No financial, operational, or clinical outcome data are provided.

Risk flags

• ●The project is at an early preclinical stage, with only in vitro results reported. This means there is a high risk that the approach may not translate to effective or safe outcomes in animal models or humans.
• ●No clinical, financial, or operational metrics are disclosed, making it impossible to assess the company's ability to fund, execute, or scale the program through subsequent development stages.
• ●The capital intensity of developing cell-based therapies and encapsulation platforms is high, and the announcement provides no information on funding, partnerships, or regulatory engagement to support the long-term development path.

Bottom line

This announcement signals technical progress for Avaí Bio and Austrianova’s joint venture, with the successful in vitro production of Klotho protein using encapsulated engineered cells. While publication in a peer-reviewed journal adds scientific credibility, the achievement is limited to laboratory proof of concept, with no animal, clinical, or commercial data disclosed. The narrative is forward-looking and aspirational, with all key milestones—preclinical validation, safety, dosing, and efficacy—still to be achieved. Investors should treat this as an early-stage scientific update, not a commercial or clinical inflection point. The most important takeaway is that the company remains in the research phase, and substantial further evidence will be required before any value realisation is possible.

Announcement summary

(OTCQB:AVAI) Avaí Bio, Inc., together with its joint venture partner Austrianova, announced the publication of a peer-reviewed article in Frontiers in Aging titled “Maintaining Klotho: Preventing the Body from Unwinding.” The article, authored by Austrianova researchers, appears in the “Interventions in Aging” section and reviews the role of Klotho in aging and age-related disease. The publication highlights the approach of Klothonova, a 50/50 joint venture between Avaí Bio and Austrianova, to achieve sustained Klotho delivery using Austrianova’s Cell-in-a-Box® technology. The article discusses scientific evidence linking declining Klotho levels to aging-related conditions such as kidney, cardiovascular, neurodegenerative, and metabolic disorders. It notes that maintaining effective Klotho protein levels is challenging due to its short half-life and limitations of conventional delivery methods. Klothonova’s program combines engineered human cells that continuously produce soluble Klotho with the Cell-in-a-Box® encapsulation platform, which encloses living cells in porous cellulose sulphate capsules allowing nutrient and protein exchange while protecting from immune attack. The Cell-in-a-Box® platform is designed to transform implanted cells into long-term biological “micro-factories” for sustained Klotho production. The publication reports that Klothonova has successfully generated Cell-in-a-Box®-encapsulated cells demonstrating long-term Klotho production and secretion in vitro, marking an important milestone for the program. The article also highlights the broader potential of Austrianova’s encapsulation platform for sustained delivery of biologically active proteins in future cell-based therapies. Additional studies are required to establish optimal dosing, long-term safety, and clinical efficacy. Prof. Walter H. Gunzburg, Chairman and Chief Scientific Officer of Austrianova, stated that publication in Frontiers journals reflects rigorous review and is an honor for the team. Brian Salmons, CEO of Austrianova, commented that the publication provides background and justification for using Cell-in-a-Box® capsules for anti-aging treatments. Klothonova, a Nevada-based company equally owned by Avaí Bio and Austrianova’s affiliate SG Austria Pte. Ltd, is focused on developing sustainable, long-term production and delivery of soluble α-Klotho using Cell-in-a-Box® encapsulated cell-based therapies. The publication provides a scientific rationale for continued development of Klothonova’s cell-based Klotho program and underscores the potential of combining cellular engineering with advanced encapsulation technology to address diseases associated with aging.

Disagree with this article?